SP
ABBV icon

Symmetry Partners’s AbbVie ABBV Stock Holding History

Symmetry Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Buy
4,845
+403
+9% +$86.7K 0.06% 75
2026
Q1 		$966K Buy
4,442
+1,106
+33% +$245K 0.06% 75
2025
Q4 		$762K Sell
3,336
-89
-3% -$20.3K 0.05% 84
2025
Q3 		$793K Buy
3,425
+483
+16% +$98.4K 0.09% 76
2025
Q2 		$546K Buy
2,942
+79
+3% +$14.7K 0.07% 84
2025
Q1 		$600K Buy
2,863
+1,032
+56% +$201K 0.08% 79
2024
Q4 		$325K Buy
1,831
+524
+40% +$96.3K 0.05% 94
2024
Q3 		$258K Sell
1,307
-13,207
-91% -$2.46M 0.06% 75
2024
Q2 		$2.49M Sell
14,514
-2,093
-13% -$347K 0.13% 69
2024
Q1 		$3.02M Sell
16,607
-1,081
-6% -$186K 0.24% 59
2023
Q4 		$2.74M Sell
17,688
-243
-1% -$35.4K 0.15% 68
2023
Q3 		$2.67M Sell
17,931
-5,164
-22% -$758K 0.14% 72
2023
Q2 		$3.11M Sell
23,095
-14,508
-39% -$2.13M 0.16% 71
2023
Q1 		$5.99M Buy
37,603
+557
+2% +$85.2K 0.33% 49
2022
Q4 		$5.99M Sell
37,046
-2,872
-7% -$440K 0.35% 46
2022
Q3 		$5.36M Buy
39,918
+10,920
+38% +$1.57M 0.36% 47
2022
Q2 		$4.44M Sell
28,998
-6,237
-18% -$953K 0.3% 47
2022
Q1 		$5.71M Buy
35,235
+6,142
+21% +$892K 0.36% 42
2021
Q4 		$3.94M Buy
29,093
+635
+2% +$75K 0.25% 52
2021
Q3 		$3.12M Sell
28,458
-800
-3% -$91.4K 0.21% 65
2021
Q2 		$3.3M Sell
29,258
-9,422
-24% -$1.06M 0.22% 73
2021
Q1 		$4.19M Buy
38,680
+254
+0.7% +$27.2K 0.3% 58
2020
Q4 		$4.12M Sell
38,426
-4,547
-11% -$437K 0.32% 49
2020
Q3 		$3.76M Buy
42,973
+23,346
+119% +$2.2M 0.32% 50
2020
Q2 		$1.93M Buy
19,627
+15,775
+410% +$1.39M 0.24% 56
2020
Q1 		$293K Buy
+3,852
New +$328K 0.07% 212

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Symmetry Partners's ABBV Position: Q2 2026 in Review

Symmetry Partners increased its AbbVie (ABBV) stake by 9.1% in Q2 2026, buying an estimated $86.7K and bringing the position to 4,845 shares worth $1.22M. The position accounts for 0.06% of the portfolio, ranked #75.

Symmetry Partners first reported a position in ABBV in Q1 2020 and has held it in 26 quarters since. The position peaked at $5.99M in Q1 2023. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Symmetry Partners held 4,845 shares of AbbVie worth $1.22M as of Q2 2026.
  • Symmetry Partners bought 403 AbbVie shares in Q2 2026, an estimated $86.7K.
  • AbbVie made up 0.06% of Symmetry Partners's portfolio in Q2 2026, its #75 holding.
  • Symmetry Partners first reported a position in AbbVie in Q1 2020 and has held it in 26 quarters since.
  • Symmetry Partners's AbbVie position peaked at $5.99M in Q1 2023.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Symmetry Partners's 13F filing for Q2 2026, filed 23 Jul 2026.